鲁索替尼治疗对骨髓纤维化及相关肿瘤中炎症介导的合并症的影响。
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
作者信息
Bjørn Mads Emil, Hasselbalch Hans Carl
机构信息
Department of Hematology, Roskilde University Hospital, Roskilde Denmark ; Institute for Inflammation Research (IIR), Department of Infectious Diseases and Rheumatology, Copenhagen University Hospital Rigshospitalet, Denmark.
Department of Hematology, Roskilde University Hospital, Roskilde Denmark.
出版信息
Clin Case Rep. 2015 Jun;3(6):499-503. doi: 10.1002/ccr3.281. Epub 2015 May 4.
Abstract
The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2 inhibitors in MF-patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation-mediated comorbidities.
摘要
骨髓纤维化（MF）及相关肿瘤（MPN）中炎症介导的合并症可能反映了MPN同时存在的免疫失调和全身性炎症本质，这强调了慢性全身性炎症、免疫失调与恶性克隆之间的联系。MF患者使用JAK1-2抑制剂可减轻全身症状和脾肿大，还可针对自身免疫性和炎症介导的合并症。
相似文献
1
The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.鲁索替尼治疗对骨髓纤维化及相关肿瘤中炎症介导的合并症的影响。
Clin Case Rep. 2015 Jun;3(6):499-503. doi: 10.1002/ccr3.281. Epub 2015 May 4.
2
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.鲁索替尼在骨髓增殖性肿瘤相关骨髓纤维化中作用的批判性评价
Onco Targets Ther. 2015 May 18;8:1091-102. doi: 10.2147/OTT.S31916. eCollection 2015.
3
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.酪氨酸激酶抑制剂在骨髓增殖性肿瘤中的作用：比较性经验教训
Onco Targets Ther. 2016 Aug 10;9:4937-57. doi: 10.2147/OTT.S102504. eCollection 2016.
4
Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.在Janus激酶抑制剂时代减轻骨髓增殖性肿瘤患者的症状负担
Leuk Lymphoma. 2015 Jul;56(7):1989-99. doi: 10.3109/10428194.2014.983098. Epub 2015 Mar 17.
5
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.骨髓增殖性肿瘤与炎症：靶向恶性克隆还是炎症过程，或者两者兼而有之。
Leukemia. 2016 May;30(5):1018-24. doi: 10.1038/leu.2016.12. Epub 2016 Feb 8.
6
Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.用于治疗骨髓增殖性肿瘤的 Janus 激酶抑制剂
Expert Opin Pharmacother. 2014 Jun;15(9):1265-76. doi: 10.1517/14656566.2014.913024. Epub 2014 Apr 25.
7
Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.芦可替尼抗炎和免疫抑制活性的潜在机制。
Front Oncol. 2019 Nov 7;9:1186. doi: 10.3389/fonc.2019.01186. eCollection 2019.
8
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.除鲁索替尼之外：fedratinib及骨髓纤维化的其他新兴治疗选择
Cancer Manag Res. 2019 Dec 24;11:10777-10790. doi: 10.2147/CMAR.S212559. eCollection 2019.
9
Inflammation and myeloproliferative neoplasms.炎症和骨髓增殖性肿瘤。
J Autoimmun. 2017 Dec;85:58-63. doi: 10.1016/j.jaut.2017.06.010. Epub 2017 Jun 30.
10
Clinical and laboratory features of myelofibrosis and limitations of current therapies.骨髓纤维化的临床和实验室特征以及当前治疗方法的局限性。
Clin Adv Hematol Oncol. 2011 Sep;9(9 Suppl 22):1-16.
引用本文的文献
1
Interleukin 6: A biomarker for COVID-19 progression.白细胞介素6：新冠病毒疾病进展的生物标志物。
Mater Today Proc. 2023;72:3351-3355. doi: 10.1016/j.matpr.2022.07.387. Epub 2022 Aug 2.
2
Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.个体合并症对骨髓纤维化患者生存的影响。
Cancers (Basel). 2022 May 9;14(9):2331. doi: 10.3390/cancers14092331.
3
Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm.白细胞介素-6：新冠病毒细胞因子风暴的元凶
Indian J Clin Biochem. 2021 Oct;36(4):440-450. doi: 10.1007/s12291-021-00989-8. Epub 2021 Jun 21.
4
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.COVID-19 作为干扰素缺乏和炎症过度活跃的中介：联合使用 JAK1/2 抑制剂与干扰素的原理。
Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14.
5
Under Development JAK Inhibitors for Dermatologic Diseases.正在研发的用于皮肤病的JAK抑制剂。
Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):137-144. doi: 10.31138/mjr.31.1.137. eCollection 2020 Jun.
6
Immunotherapy in Myeloproliferative Diseases.免疫疗法在骨髓增殖性疾病中的应用。
Cells. 2020 Jun 26;9(6):1559. doi: 10.3390/cells9061559.
7
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.COVID-19：最新可用药物和 SARS-CoV-2 疗法综述。凝血与炎症相互作用。
Virus Res. 2020 Sep;286:198070. doi: 10.1016/j.virusres.2020.198070. Epub 2020 Jun 20.
8
SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.严重急性呼吸综合征冠状病毒2型与冠状病毒病2019：白细胞介素-6（IL-6）是急性呼吸窘迫综合征发病的“罪魁祸首”吗？除了托珠单抗还有什么？可溶性糖蛋白130融合蛋白（SGP130Fc）
Cytokine X. 2020 Jun;2(2):100029. doi: 10.1016/j.cytox.2020.100029. Epub 2020 May 14.
9
Immunoproteasome Genes Are Modulated in CD34 JAK2 Mutated Cells from Primary Myelofibrosis Patients.免疫蛋白酶体基因在原发性骨髓纤维化患者的 CD34 JAK2 突变细胞中受到调节。
Int J Mol Sci. 2020 Apr 22;21(8):2926. doi: 10.3390/ijms21082926.
10
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms.活性氧在骨髓纤维化及相关肿瘤中的作用
Mediators Inflamm. 2015;2015:648090. doi: 10.1155/2015/648090. Epub 2015 Oct 11.
本文引用的文献
1
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.恶性和非恶性细胞中的JAK-STAT信号通路激活有助于骨髓增殖性肿瘤的发病机制和治疗反应。
Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.
2
Remission of recalcitrant dermatomyositis treated with ruxolitinib.用鲁索替尼治疗顽固性皮肌炎的缓解情况。
N Engl J Med. 2014 Dec 25;371(26):2537-8. doi: 10.1056/NEJMc1412997.
3
Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.全血转录谱分析揭示骨髓纤维化及相关肿瘤中氧化和抗氧化防御基因的失调。Nrf2下调对基因组不稳定和疾病进展的潜在影响。
PLoS One. 2014 Nov 14;9(11):e112786. doi: 10.1371/journal.pone.0112786. eCollection 2014.
4
Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera.干扰素与JAK1-2抑制剂联合治疗是可行的：真性红细胞增多症中JAK2V617F等位基因负担快速降低的概念验证。
Leuk Res Rep. 2014 Aug 1;3(2):73-5. doi: 10.1016/j.lrr.2014.05.003. eCollection 2014.
5
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.鲁索替尼使一名原发性血小板增多症患者的全秃得以逆转。
Am J Hematol. 2015 Jan;90(1):82-3. doi: 10.1002/ajh.23871.
6
Ruxolitinib and survival improvement in patients with myelofibrosis.
Leukemia. 2015 Mar;29(3):739-40. doi: 10.1038/leu.2014.282. Epub 2014 Sep 24.
7
An immune dysregulation in MPN.骨髓增殖性肿瘤中的免疫失调。
Curr Hematol Malig Rep. 2014 Dec;9(4):331-9. doi: 10.1007/s11899-014-0227-0.
8
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.斑秃由细胞毒性 T 淋巴细胞驱动，并可被 JAK 抑制逆转。
Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17.
9
Ruxolitinib Enhances Platelet Production in Patients With Thrombocytopenic Myelofibrosis.芦可替尼可提高血小板减少性骨髓纤维化患者的血小板生成。
J Clin Oncol. 2016 Feb 10;34(5):e38-40. doi: 10.1200/JCO.2013.51.0057. Epub 2014 Jun 23.
10
Comorbidities predict worse prognosis in patients with primary myelofibrosis.合并症预测原发性骨髓纤维化患者预后更差。
Cancer. 2014 Oct 1;120(19):2996-3002. doi: 10.1002/cncr.28857. Epub 2014 Jun 10.
Zotero 插件